NAYA Biosciences (NAYA) Files DEFA14A Proxy Materials – No Fee
NAYA Biosciences, Inc. has submitted a Schedule 14A – Definitive Additional Materials (Form DEFA14A) with the U.S. Securities and Exchange Commission.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NAYA Biosciences, Inc. has submitted a Schedule 14A – Definitive Additional Materials (Form DEFA14A) with the U.S. Securities and Exchange Commission. The filing indicates that the company, listed in the document under the legal name INVO Fertility, Inc., is providing supplemental proxy solicitation materials rather than a full definitive proxy statement. According to the cover page, the materials are filed by the registrant and no filing fee is required for this submission. No financial data, transaction details, or voting proposals are included in the excerpt provided.
Insights
TL;DR: Routine DEFA14A filing; provides supplemental proxy info, no fee, no material impact.
This is a standard Definitive Additional Proxy Material filing (DEFA14A). Such filings typically supply shareholders with clarifying or additional information ahead of a meeting but seldom introduce new strategic actions. The absence of financial tables, proposals, or transaction disclosures implies that the content is purely administrative. Because no fee is due and no new items are flagged, the filing is unlikely to influence valuation or voting outcomes. Investors should await further proxy documentation for any actionable details.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What type of SEC filing did NAYA Biosciences (NAYA) submit?
Does the DEFA14A filing by NAYA Biosciences require a fee?
Who is listed as the registrant in the filing?
Are there any financial statements or earnings data included in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
| Filed by the Registrant  ☒ | Filed by a Party other than the Registrant  ☐ |
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| | |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| | |
| ☐ | Definitive Proxy Statement |
| | |
| ☒ | Definitive Additional Materials |
| | |
| ☐ | Soliciting Material Pursuant to §240.14a-12 |
INVO FERTILITY, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. |
| | |
| ☐ | Fee paid previously with preliminary materials. |
| | |
| ☐ | Fee computed on table in exhibit required by Item 2(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
